New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
07:14 EDTHTBXHeat Biologics reports Q2 EPS (44c), consensus (40c)
The company said, "The increase in the loss was primarily attributable to an increase of $160,380 in Research and Development expense, an increase of $658,252 in Clinical and Regulatory expense and an increase of $576,708 in General and Administrative expense."
News For HTBX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for HTBX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use